A- A A+

Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.

Versfeld, A., McBride, A., Scheibe, A. et al. 

Harm Reduct J 17, 39 (2020). doi.org/10.1186/s12954-020-00382-3

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-020-00382-3

Hepatitis B Virus DNA is a Substrate for the cGAS/STING Pathway but is not Sensed in Infected Hepatocytes.

Lauterbach-Rivière, L.; Bergez, M.; Mönch, S.; Qu, B.; Riess, M.; Vondran, F.W.R.; Liese, J.; Hornung, V.; Urban, S.; König, R. 

Viruses 2020, 12, 592. 

https://www.mdpi.com/1999-4915/12/6/592

Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada 

Broad J, Mason K, Guyton M, Lettner B, Matelski J, Powis J. 

[published online ahead of print, 2020 May 13]. Int J Drug Policy. 2020;80:102755. doi:10.1016/j.drugpo.2020.102755

https://www.sciencedirect.com/science/article/pii/S0955395920300967

Prisoners should not be left behind in HCV research and policies. 

Moazen, B., Stöver, H., Dolan, K. et al. 

Harm Reduct J 17, 33 (2020). doi.org/10.1186/s12954-020-00379-y

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-020-00379-y

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.

Hinrichsen H, Stoehr A, Cornberg M, Klinker H, Heyne R, John C, Simon KG, Guenther V, Martin K, Witte V, Zeuzem S.

Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/32345848

The global prevalence of hepatitis D virus infection: systematic review and meta-analysis.

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM.

J Hepatol. 2020 Apr 23. pii: S0168-8278(20)30220-8. doi: 10.1016/j.jhep.2020.04.008. 

https://www.journal-of-hepatology.eu/article/S0168-8278(20)30220-8/pdf

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria.

Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, et al. (2020) 

PLoS ONE 15(3): e0229239. doi.org/10.1371/journal.pone.0229239

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229239

Risk of Hepatitis C Virus Infection in Injecting and Non-Injecting Drug Users Receiving Opioid Substitution Therapy.

Wang CW, Chuang HY, Chiang HC, Huang PC, Yu ML, Dai CY.

J Chin Med Assoc. 2020 Mar 26. doi: 10.1097/JCMA.0000000000000312. 

https://journals.lww.com/jcma/Abstract/latest/Risk_of_Hepatitis_C_Virus_Infection_in_Injecting.99769.aspx

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting.

Koustenis KR, Anagnostou O, Kranidioti H, Vasileiadi S, Antonakaki P, Koutli E, Pantsas P, Deutsch M, Manolakopoulos S.

Ann Gastroenterol. 2020 Mar-Apr;33(2):195-201. doi: 10.20524/aog.2020.0449.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049240/

Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis.

Perazzo H, Castro R, Luz PM, Banholi M, Goldenzon RV, Cardoso SW, Grinsztejn B, Veloso VG.

Bull World Health Organ. 2020 Mar 1;98(3):188-197K. doi: 10.2471/BLT.19.231522. 

https://www.ncbi.nlm.nih.gov/pubmed/32132753

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.

Charatcharoenwitthaya P, Wongpaitoon V, Komolmit P, Sukeepaisarnjaroen W, Tangkijvanich P, Piratvisuth T, Sanpajit T, Sutthivana C, Bunchorntavakul C, Sobhonslidsuk A, Chonprasertsuk S, Siripipattanamongkol C, Sethasine S, Tanwandee T; THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C.

BMC Gastroenterol. 2020 Mar 5;20(1):47. doi: 10.1186/s12876-020-01196-0.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057522/

Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.

Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T.

Oncol Lett. 2020 Mar;19(3):2205-2212. doi: 10.3892/ol.2020.11341. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038998/

USA. Opioid-Krise: US-Experten fordern Hepatitis C-Screening aller Erwachsenen

Washington – Die US Preventive Services Task Force (USPSTF) rät allen Erwachsenen im Alter von 18 bis 79 Jahren, sich auf Hepatitis C-Screening testen zu lassen.

Die entsprechende Grad B-Empfehlung wurde im Amerikanischen Ärzteblatt (JAMA 2020; doi: 10.1001/jama.2020.1123) veröffentlicht und mit einem Evidenz-Report begründet (JAMA 2020; doi: 10.1001/jama.2019.20788). Hintergrund ist eine steigende Zahl von Hepatitis C-Erkrankungen infolge der Opioid-Krise und ein Preisrückgang bei den Medikamenten. (aerzteblatt.de, 10.03.2020)

https://www.aerzteblatt.de/nachrichten/110850/Opioid-Krise-US-Experten-fordern-Hepatitis-C-Screening-aller-Erwachsenen

Studie: ASS könnte Hepatitis-Infizierte vor Leberkrebs schützen

Stockholm – Schwedische Erwachsene mit Hepatitis B oder C, die aus anderen Gründen über längere Zeit niedrig dosiert mit Acetylsalicylsäure (ASS) behandelt wurden, erkrankten in einer epidemiologischen Studie im New England Journal of Medicine (2020; 382: 1018-1028) in den Folgejahren seltener an einem hepatozellulären Karzinom. Eine erhöhte Rate von gastrointestinalen Blutungen wurde nicht gefunden. (aerzteblatt.de, 12.03.2020)

https://www.aerzteblatt.de/nachrichten/111032/Studie-ASS-koennte-Hepatitis-Infizierte-vor-Leberkrebs-schuetzen

Drug-Induced Liver Injury EASL Guideline

Idiosyncratic (unpredictable) Drug-Induced Liver Injury is one of the most challenging liver disorders faced by hepatologists. This happens because of the myriad of drugs used in clinical practice. Also due to the available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers.  Therefore, this makes the diagnosis of Drug-Induced Liver Injury an uncertain process. One that requires a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe. It can lead to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed.
This Clinical Practice Guideline summarizes the available evidence on risk factors, diagnosis, management, risk minimization strategies for Drug-Induced Liver Injury. (EASL - The European Association for the Study of the Liver, April 2019) 

https://easl.eu/publication/cpg-drug-induced-liver-injury

A New Generation of Drug Users in St. Petersburg, Russia? HIV, HCV, and Overdose Risks in a Mixed-Methods Pilot Study of Young Hard Drug Users.

Meylakhs P, Friedman SR, Meylakhs A, Mateu-Gelabert P, Ompad DC, Alieva A, Dmitrieva A.

AIDS Behav. 2019 Dec;23(12):3350-3365. doi: 10.1007/s10461-019-02489-6.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788941/

Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.

Schulte B, Wübbolding M, Marra F, Port K, Manns MP, Back D, Cornberg M, Stichtenoth DO, Höner Zu Siederdissen C, Maasoumy B.

Open Forum Infect Dis. 2020 Feb 3;7(2):ofaa040. doi: 10.1093/ofid/ofaa040.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033915/

Hepatitis C Virus Vaccine: Challenges and Prospects.

Duncan JD, Urbanowicz RA, Tarr AW, Ball JK.

Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090. Review.

https://www.mdpi.com/2076-393X/8/1/90

Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection.

Ibrahim MG, Sharafeldin AA, Mousa NI, Mousa TK, El Missiri AM.

Egypt Heart J. 2020 Feb 7;72(1):7. doi: 10.1186/s43044-020-0042-y.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005241/

Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment.

Kim NJ, Pearson M, Vutien P, Su F, Moon AM, Berry K, Green PK, Williams EC, Ioannou GN.

Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996340/

Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program.

Abdel-Razek W, Hassany M, El-Sayed MH, El-Serafy M, Doss W, Esmat G, Waked I.

Clin Liver Dis (Hoboken). 2020 Jan 29;14(6):203-206. doi: 10.1002/cld.868. eCollection 2019 Dec. Review. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988418/

High hepatitis C virus infection among female sex workers in Viet Nam: strong correlation with HIV and injection drug use.

Le LN, O'Connor S, Tran TH, Maher L, Kaldor J, Sabin K, Tran HV, Tran QD, Ho VAT, Nguyen TA.

Western Pac Surveill Response J. 2019 Jul 25;10(3):9-18. doi: 10.5365/wpsar.2019.10.1.002.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024697/

Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.

Murai K, Hikita H, Kai Y, Kondo Y, Fukuoka M, Fukutomi K, Doi A, Yamai T, Nakabori T, Fukuda R, Takahashi T, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.

Sci Rep. 2020 Jan 22;10(1):941. doi: 10.1038/s41598-020-57603-9.

https://www.nature.com/articles/s41598-020-57603-9

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany.

Runge M, Krensel M, Westermann C, Bindl D, Nagels K, Augustin M, Nienhaus A.

Int J Environ Res Public Health. 2020 Jan 9;17(2). pii: E440. doi: 10.3390/ijerph17020440.

https://www.mdpi.com/1660-4601/17/2/440

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.

Nardelli S, Riggio O, Rosati D, Gioia S, Farcomeni A, Ridola L.

World J Gastroenterol. 2019 Dec 28;25(48):6928-6938. doi: 10.3748/wjg.v25.i48.6928.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938730/

A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran.

Behzadifar M, Behzadifar M, Bragazzi NL.

BMC Public Health. 2020 Jan 14;20(1):62. doi: 10.1186/s12889-020-8175-1.

https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-8175-1

The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa.

Mahmud, S., Mumtaz, G. R., Chemaitelly, H., Al Kanaani, Z., Kouyoumjian, S. P., Hermez, J. G., and Abu‐Raddad, L. J. ( 2020) 

Addiction, doi.org/10.1111/add.14944.

https://onlinelibrary.wiley.com/doi/full/10.1111/add.14944

Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey.

Van Baelen L, Plettinckx E, Antoine J, Gremeaux L.

Harm Reduct J. 2020 Feb 21;17(1):11. doi: 10.1186/s12954-020-00358-3.

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-020-00358-3

ACCESS TO HEPATITIS C TREATMENT AND CARE AMONG PEOPLE WHO INJECT DRUGS: FAILING PEOPLE MOST DISPROPORTIONATELY AFFECTED

(HepCoalition.org, Frankreich/USA, ISSUE BRIEF FEBRUARY 2020

https://hepcoalition.org/learn/care/article/access-to-hepatitis-c-treatment-and-care-among-people-who-inject-drugs-failing

Leberzirrhose: Empfehlungen zur sicheren Anwendung von Arzneimitteln

Berlin – Eine Leberzirrhose bei einem Patienten kann bekanntlich den Stoffwechsel und die Dosis-Wirkungsbeziehung von Arzneimitteln verändern und das Risiko von Nebenwirkungen erhöhen. Eine niederländische Arbeitsgruppe hat nun evidenzbasierte Empfehlungen für den Einsatz und die Dosierung zahlreicher praxisrelevanter Arzneimittel bei Leberzirrhose erarbeitet. (aerzteblatt.de, 04.02.2020)

https://www.aerzteblatt.de/nachrichten/109152/Leberzirrhose-Empfehlungen-zur-sicheren-Anwendung-von-Arzneimitteln